No

Anticholinergic Agent; Antispasmodic Agent, Gastrointestinal

Management of peptic ulcer disease; inhibit salivation and excessive secretions in respiratory tract preoperatively

C

Angle-closure glaucoma; acute hemorrhage; tachycardia; hypersensitivity to mepenzolate or any component; obstructive uropathy (ie, bladder neck obstruction due to prostatic hypertrophy); obstructive gastrointestinal disease (ie, pyloroduodenal stenosis, achalasia); paralytic ileus; intestinal atony of the debilitated or elderly patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis or toxic megacolon complicating ulcerative colitis; myasthenia gravis; allergic or idiosyncratic reactions of related compounds

>10%:

Gastrointestinal: Constipation, xerostomia, dry throat

Dermatologic: Dry skin

Respiratory: Dry nose

Miscellaneous: Decreased diaphoresis

1% to 10%: Gastrointestinal: Dysphagia

Adults: Oral: 25-50 mg 4 times/day with meal and at bedtime

May be administered with meals

May rarely cause confusion, amnesia, drowsiness, nervousness, or insomnia

Concurrent use with psychotropics may produce additive drowsiness or anticholinergic side effects (dry mouth)

No information available to require special precautions

>10% of patients experience dry mouth

Tablet, as bromide: 25 mg